Ginkgo Bioworks DNA Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)

Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year) at other companies

AzentaAZTA

——

Bio-Rad LaboratoriesBIO

——

Other financials

Income statement

See full

Revenue$19.5M-49.1%

Gross profit$16.4M-52.0%

Operating income-$71.4M+11.9%

Net income-$82.6M+9.2%

EPS (diluted)-$1.42+27.6%

Balance sheet

See full

Cash & equivalents$188.7M-46.9%

Total debt$410.7M-5.5%

Total equity$443.2M-31.6%

Total assets$1.0B-20.1%

Cash flow

See full

Operating cash flow-$46.7M+9.4%

CapEx$1.9M-74.6%

Free cash flow-$48.6M+17.8%

Valuation

See full

Market cap$625.16M+24.6%

Enterprise value$847.19M+45.9%

P/S4.4×+2.2×

Profitability

See full

Operating margin-210.7%+7.6pp

Net margin-215.4%+8.3pp

FCF margin-119%-21.2pp

Returns & leverage

See full

Return on equity-55.8%-1.8pp

Debt / equity0.9×+0.3×

Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's available-for-sale debt securities - amortized cost (due within one year).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ginkgo Bioworks's available-for-sale debt securities - amortized cost (due within one year)?: Ginkgo Bioworks (DNA) reported available-for-sale debt securities - amortized cost (due within one year) of $179.18M in Q1 2026.